1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Panaxia Labs Israel Ltd
  6. News
  7. Summary
    PNAX   IL0011043630

PANAXIA LABS ISRAEL LTD

(PNAX)
  Report
End-of-day quote TEL AVIV STOCK EXCHANGE  -  05-18
0.6230 ILS   +0.16%
03/31Panaxia Labs Israel Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Panaxia Labs Israel Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/29/2021 | 01:38am EDT

Panaxia Labs Israel Ltd reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was ILS 22.5 million compared to ILS 16.85 million a year ago. Net loss was ILS 6.43 million compared to ILS 8.41 million a year ago. Basic loss per share from continuing operations was ILS 0.04 compared to ILS 0.07 a year ago. For the nine months, sales was ILS 59.79 million compared to ILS 43.79 million a year ago. Net loss was ILS 11.08 million compared to ILS 26.56 million a year ago. Basic loss per share from continuing operations was ILS 0.08 compared to ILS 0.25 a year ago.


© S&P Capital IQ 2021
All news about PANAXIA LABS ISRAEL LTD
03/31Panaxia Labs Israel Ltd Reports Earnings Results for the Full Year Ended December 31, 2..
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Third Quarter and Nine Months ..
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Second Quarter Ended June 30, ..
CI
2021Panaxia Labs Israel Ltd. and Neuraxpharm Expands Strategic Collaboration to Poland
CI
2021IM Cannabis Corp.
AQ
2021IMC Holdings Ltd. agreed to acquire Israel's Largest Retail and Online Pharmacy Busines..
CI
2021Panaxia Labs Israel Ltd Provides Revenue Guidance for the First Quarter of 2021
CI
2021Panaxia Labs Israel Ltd Reports Earnings Results for the Fourth Quarter and Year 2020
CI
2021Government of Cyprus Selects Panaxia Labs Israel Ltd. to Supply Premium Oils
CI
2021Neuraxpharm France and Panaxia Labs Select the Participation in A Pilot Program for the..
CI
More news
Financials
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 93,3 M 27,7 M 27,7 M
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 33,5%
Chart PANAXIA LABS ISRAEL LTD
Duration : Period :
Panaxia Labs Israel Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Dadi Segal Chief Executive Officer & Director
Jonathan B. Kolber Chairman
Eran Goldberg Chief Technology Officer
Tamar Hinenzon Meiri Vice President-Operations
Tal Yaron Eldar Independent External Director
Sector and Competitors
1st jan.Capi. (M$)
PANAXIA LABS ISRAEL LTD-33.93%28
CINTAS CORPORATION-17.95%36 714
TELEPERFORMANCE SE-21.96%18 887
BUREAU VERITAS SA-9.36%12 545
EDENRED SE11.51%11 849
LG CORP.-6.06%10 288